Skip to content
Tafluprost
Zioptan (tafluprost) is a small molecule pharmaceutical. Tafluprost was first approved as Zioptan on 2012-02-10. It is used to treat open-angle glaucoma in the USA. The pharmaceutical is active against prostaglandin F2-alpha receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Zioptan (generic drugs available since 2019-08-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tafluprost
Tradename
Company
Number
Date
Products
ZIOPTANThea PharmaN-202514 RX2012-02-10
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
tafluprostANDA2022-12-21
tafluprostANDA2022-12-21
zioptanNew Drug Application2022-10-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
open-angle glaucomaEFO_0004190D005902H40.1
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Tafluprost, Zioptan, Thea Pharma
99995932029-05-28DP
108641592029-05-28DPU-778
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EE: Prostaglandin analogues, antiglaucoma drugs and miotics
— S01EE05: Tafluprost
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vivax malariaD016780EFO_0007445B514331213
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B54231——6
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Falciparum malariaD016778EFO_0007444B50—3———3
Covid-19D000086382U07.1—1———1
Healthy volunteers/patients——1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Glucosephosphate dehydrogenase deficiencyD005955EFO_0007287————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTAFLUPROST
INNtafluprost
Description
Tafluprost is a prostaglandin Falpha that is prostaglandin F2alpha in which the carboxylic acid function has been converted to the corresponding isopropyl ester and the 3-hydroxy-1-octenyl side-chain is substituted by 3,3-difluoro-4-phenoxybut-1-enyl. Used for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It has a role as a prostaglandin receptor agonist. It is a prostaglandins Falpha, an organofluorine compound and an isopropyl ester. It is functionally related to a prostaglandin F2alpha.
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1
Identifiers
PDB—
CAS-ID209860-87-7
RxCUI1244607
ChEMBL IDCHEMBL1963683
ChEBI ID66899
PubChem CID9868491
DrugBankDB08819
UNII ID1O6WQ6T7G3 (ChemIDplus, GSRS)
Target
Agency Approved
PTGFR
PTGFR
Organism
Homo sapiens
Gene name
PTGFR
Gene synonyms
NCBI Gene ID
5737
Protein name
prostaglandin F2-alpha receptor
Protein synonyms
FP prostanoid receptor, PGF receptor, PGF2 alpha receptor, prostaglandin receptor (2-alpha), Prostanoid FP receptor
Uniprot ID
Q9P1X4
Mouse ortholog
Ptgfr (19220)
prostaglandin F2-alpha receptor (P43117)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Zioptan - Akorn
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 647 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
36 adverse events reported
View more details